Managers / Q3 2021 · view latest →
Gates Foundation
CIK 0001663801 · 500 5TH AVE NORTH, SEATTLE, WA, 98109 · 206-709-3100
Summary
Gates Foundation reported $342M in U.S.-listed holdings across 10 positions for Q3 2021.
The portfolio is heavily concentrated: Curevac N V alone accounts for 50.1% of reported value.
Compared with Q2 2021, the fund opened 2 new positions and exited 0.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Other · 63.6% · $217M
- Common Stock · 18.2% · $62M
- ADR · 18.1% · $62M
Quarter-over-Quarter Changes full breakdown →
vs Q2 2021 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| LUMIRADX LIMITED | NEW | +5.57M | 5.57M | +$46M | $46M |
| SERASERA PROGNOSTICS INC | NEW | +779.8K | 779.8K | +$9M | $9M |
| BNTXBIONTECH SE | TRIMMED | −890.0K | 148.7K | −$192M | $41M |
| VIRVIR BIOTECHNOLOGY INC | TRIMMED | −2.10M | 677.8K | −$102M | $30M |
| IMCRIMMUNCORE HLDGS PLC | TRIMMED | −1.05M | 576.9K | −$43M | $21M |
| CUREVAC N V | HELD | +0 | 3.13M | −$59M | $171M |
| BFLYBUTTERFLY NETWORK INC | HELD | +0 | 1.01M | −$4M | $11M |
| ATRECA INC | HELD | +0 | 1.40M | −$3M | $9M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2021
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | CUREVAC N V | COM | 50.12% | $171M | 3.13M |
| 2 | LUMIRADX LIMITED | SHS | 13.50% | $46M | 5.57M |
| 3 | BNTXBIONTECH SEhistory → | SPONSORED ADS | 11.89% | $41M | 148.7K |
| 4 | VIRVIR BIOTECHNOLOGY INChistory → | COM | 8.64% | $30M | 677.8K |
| 5 | IMCRIMMUNCORE HLDGS PLChistory → | ADS | 6.26% | $21M | 576.9K |
| 6 | BFLYBUTTERFLY NETWORK INChistory → | CL A COM | 3.10% | $11M | 1.01M |
| 7 | ATRECA INC | CL A COM | 2.55% | $9M | 1.40M |
| 8 | SERASERA PROGNOSTICS INChistory → | CL A COM | 2.55% | $9M | 779.8K |
| 9 | AMYRIS INC | COM NEW | 1.17% | $4M | 292.4K |
| 10 | ZYUSDZYMERGEN INC | COM | 0.23% | $800,000 | 60.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2024 | $44M | 5 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $60M | 6 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $84M | 8 | May 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $90M | 8 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $84M | 9 | Nov 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $126M | 9 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $113M | 9 | May 12, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $130M | 9 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $127M | 10 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $130M | 9 | Aug 12, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $186M | 11 | May 13, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $330M | 11 | Feb 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $342M | 10 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $692M | 8 | Aug 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $656M | 7 | May 14, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $438M | 5 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.